
Acquisition - August 26, 2015
Recipharm signs agreement with RedHill Biopharma
Recipharm has announces that it has signed an agreement with Israeli biopharmaceutical company RedHill Biopharma for the manufacturing of RedHill’s leading, late-stage patented drug candidate, RHB-105. RHB-105 is being developed for the treatment of Helicobacter pylori (H. pylori) bacterial infection, a global market estimated at about $4.8 billion. Recipharm will be responsible for the supply […]